ArticleEmerging microbes & infections2019
Genomic epidemiology of erythromycin-resistant Bordetella pertussis in China.
Article in Emerging microbes & infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Antimicrobial resistance inEpidemiology and infection · 2026Pooled it
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- Co-infection with macrolide-resistant and macrolide-susceptibleASM case reports · 2026Article
- Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis.The Journal of antimicrobial chemotherapy · 2026Article
- Genomic insights into Bordetella pertussis evolution and macrolide resistance in Yiwu, China.BMC genomics · 2025Article
- Molecular epidemiology and genomic features of Bordetella pertussis in Tianjin, China, 2023.BMC microbiology · 2025Article
- Waning immunity, prevailing non-vaccine typeThe Lancet regional health. Western Pacific · 2025Article
- Vaccine antigen-based genotyping ofMicrobiology spectrum · 2025Article
- Article
- Effect of Early Administration of Clarithromycin or Azithromycin on Symptoms of Pertussis in Infants.Antibiotics (Basel, Switzerland) · 2025Article
- Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.Infection & chemotherapy · 2025Review
- Article
- DecipheringJournal of clinical microbiology · 2024Article
- Emergence of Erythromycin-Resistant and Pertactin- and Filamentous Hemagglutinin-DeficientChina CDC weekly · 2024Article
- StrengtheningJournal of clinical microbiology · 2024Article
- Whole-genome comparison of two same-genotype macrolide-resistant Bordetella pertussis isolates collected in Japan.PloS one · 2024Article
- Molecular characterization and antimicrobial susceptibility for 62 isolates ofFrontiers in microbiology · 2024Article
- Genomic epidemiology and multilevel genome typing ofEmerging microbes & infections · 2023Article
- Whole-Genome Analysis of Bordetella pertussis MT27 Isolates from School-Associated Outbreaks: Single-Nucleotide Polymorphism Diversity and Threshold of the Outbreak Strains.Microbiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolides such as erythromycin are the empirical treatment of Bordetella pertussis infections. China has experienced an increase in erythromycin-resistant B. pertussis isolates since they were first reported in 2013. Here, we undertook a genomic study on Chinese B. pertussis isolates from 2012 to 2015 to elucidate the origins and phylogenetic relationships of erythromycin-resistant B. pertussis isolates in China. A total of 167 Chinese B. pertussis isolates were used for antibiotic sensitivity testing and multiple locus variable-number tandem repeat (VNTR) analysis (MLVA). All except four isolates were erythromycin-resistant and of the four erythromycin-sensitive isolates, three were non-ptxP1. MLVA types (MT), MT55, MT104 and MT195 were the predominant types. Fifty of those isolates were used for whole genome sequencing and phylogenetic analysis. Genome sequencing and phylogenetic analysis revealed three independent erythromycin-resistant lineages and all resistant isolates carried a mutation in the 23S rRNA gene. A novel fhaB3 allele was found uniquely in Chinese ptxP1 isolates and these Chinese ptxP1-ptxA1-fhaB3 had a 5-fold higher mutation rate than the global ptxP1-ptxA1 B. pertussis population. Our results suggest that the evolution of Chinese B. pertussis is likely to be driven by selection pressure from both vaccination and antibiotics. The emergence of the new non-vaccine fhaB3 allele in Chinese B. pertussis population may be a result of selection from vaccination, whereas the expansion of ptxP1-fhaB3 lineages was most likely to be the result of selection pressure from antibiotics. Further monitoring of B. pertussis in China is required to better understand the evolution of the pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.